8TH international rasopathies symposium: expanding research and care practice through global collaboration and advocacy

Ended Project Grant Awarded Last action

Award ID
R13TR004509
Recipient
Awarding agency
Obligated
$21,000

Award facts

Completion date
Funding agency
National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
RAS-RAF-MEK-ERK signaling pathway dysregulation is responsible for a large group of human congenital syndromes collectively termed rasopathies that share a pathogenic mechanism of elevated RAS/ERK signaling and overlapping clinical features. Rasopathy syndromes fall along a spectrum with variable, multisystem complications reflecting the essential and widespread role of RAS signaling throughout development. The medical, financial, and social burden on families can be substantial. Some of the rasopathies (e.g., costello, cardiofaciocutaneous, legius syndromes) are relatively rare, whereas noonan syndrome and neurofibromatosis type 1 are estimated to affect 1:1000-1:2500 people. The study of rare diseases necessitates inclusion of broad expertise and partner networks to reach critical mass for productive insights. To advance understanding of all rasopathies, we seek funding to convene the 8TH international rasopathies symposium: expanding research and care practice through global collaboration and advocacy, a hybrid, virtual/in-person event in denver, colorado on july 21-23, 2023. This format is expected to attract the greatest participation of clinicians, researchers, trainees, biopharma companies, advocates, and affected rasopathy families from the international community. The symposium is distinguished from others by being highly multidisciplinary, science-focused and inclusive of advocates and families, and distinct from targeted oncology or RAS-associated drug discovery meetings. The organizing committee of parent advocates, academic and clinical chairs, consists of three women and two people of color. A diverse group of presenters, panelists, and moderators, including early-stage investigators, will convene to discuss (i) quality of life issues, (II) recent clinical progress, (III) neurodevelopment from brain to behavior, (IV) disordered metabolism, (v) feeding and gastrointestinal challenges, (VI) current therapeutic landscape and advances in drug discovery, (VII) genotype-phenotype correlations, and (VIII) global collaborations and advocacy. Conference advertisements will specifically welcome underrepresented groups and new investigators to increase the talent pool from which to build an international network of researchers, benefitting the broader scientific and rasopathies communities. Funds are requested to support travel/lodging for organizers and speakers, scholarships for trainees/early-stage investigators whose meritorious abstracts are selected for presentation, and implementation of the hybrid conference logistics.

Transactions

Action Obligated Date
Amendment $0
Amendment $3,000
Amendment $15,000
Original award $3,000

Quick answers

Who received award R13TR004509?

R13TR004509 was awarded to Rasopathies Network USA by National Center for Advancing Translational Sciences (National Institutes of Health) on May 1, 2023.

How much is award R13TR004509 worth?

$21,000 has been obligated on R13TR004509.

Which agency awarded R13TR004509?

National Center for Advancing Translational Sciences (National Institutes of Health) awarded R13TR004509, with funding from National Institute of Child Health and Human Development (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login